



#7 Box 509
0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

WOLOZIN et al.

Serial Number: 09/ 901,187

Group Art Unit: not assigned

Filed: July 9, 2001

Examiner: not assigned

For: Methods for Preventing Neural Tissue Damage and for the Treatment of Alpha-Synuclein Diseases

Resubmission of Computer Readable Form

Commissioner for Patents
Washington, D.C. 20231

March 22, 2002

Sir:

In response to the Notice indicating a CRF Problem, dated January 30, 2002, Applicants hereby submit another diskette that contains the Sequence Listing (named "wolozin"). This CRF contains a sequence listing that is identical to the paper copy and the previous CRF. No changes have been made.

It is respectfully requested that this CRF be made of record in this application.
No fee is due with this paper.

Respectfully submitted,

Mary E. Gormley
Attorney for Applicants
Registration No. 34,409

Docket No.: PAN01/002US
Panacea Pharmaceuticals, Inc.
9700 Great Seneca Hwy.
Rockville, Maryland 20850
Tel: (240) 453-6295
Enclosures: Copy of Notice; CRF (diskette)

I certify that this correspondence is being deposited with the US Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date: 3/22/02

By:
Mary E. Gormley



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/901,187	07/09/2001	Benjamin Wolozin	PAN01/002US

CONFIRMATION NO. 6018

29100
PANACEA PHARMACEUTICALS, INC.
9700 GREAT SENECA HIGHWAY
ROCKVILLE, MD 20850

FORMALITIES LETTER



OC000000007388685

Date Mailed: 01/30/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE